Carregant...
Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
Crohn’s disease is characterized by a dysregulation of both innate and adaptive immunity responses. Interleukin-12/23 (IL-12/23) pathway has been found to be a major driver of inflammation in adaptive immune responses. Ustekinumab is a fully human immunoglobulin G1 kappa monoclonal antibody that blo...
Guardat en:
| Publicat a: | Drug Des Devel Ther |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5113936/ https://ncbi.nlm.nih.gov/pubmed/27956825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S102141 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|